Patient-Provider Communication: The Key to Improving IBS-C Management.
作者信息
Hanson Christina
机构信息
South Denver Gastroenterology Englewood, Colorado.
出版信息
Gastroenterol Hepatol (N Y). 2025 Jan;21(1):28-39.
Abstract
摘要
相似文献
1
Patient-Provider Communication: The Key to Improving IBS-C Management.患者与医护人员的沟通：改善便秘型肠易激综合征管理的关键
Gastroenterol Hepatol (N Y). 2025 Jan;21(1):28-39.
2
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.美国便秘型肠易激综合征患者负担及治疗前景综述
Clin Exp Gastroenterol. 2024 Aug 2;17:227-253. doi: 10.2147/CEG.S464375. eCollection 2024.
3
Racial disparity in healthcare utilization among patients with Irritable Bowel Syndrome: results from a multicenter cohort.肠易激综合征患者医疗利用中的种族差异：一项多中心队列研究结果。
Neurogastroenterol Motil. 2021 May;33(5):e14039. doi: 10.1111/nmo.14039. Epub 2020 Dec 1.
4
Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey.肠易激综合征患者对医疗保健提供者的理想期望和近期体验：一项全国性调查。
Dig Dis Sci. 2010 Feb;55(2):375-83. doi: 10.1007/s10620-009-0855-8. Epub 2009 Jun 10.
5
Irritable Bowel Syndrome: Patient-Provider Interaction and Patient Education.肠易激综合征：医患互动与患者教育
J Clin Med. 2018 Jan 2;7(1):3. doi: 10.3390/jcm7010003.
6
IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study.肠易激综合征患者的治疗预期和动机对与提供者的治疗联盟质量有影响：肠易激综合征结局研究结果。
J Clin Gastroenterol. 2021;55(5):411-421. doi: 10.1097/MCG.0000000000001343.
7
Differences in provider recommendations for Black/African American and White patients with irritable bowel syndrome.提供者对患有肠易激综合征的黑种人/非裔美国人和白人患者的建议存在差异。
Neurogastroenterol Motil. 2024 Mar;36(3):e14742. doi: 10.1111/nmo.14742. Epub 2024 Jan 23.
8
Patient preferences of healthcare delivery in irritable bowel syndrome: a focus group study.肠易激综合征患者对医疗服务传递的偏好：一项焦点小组研究。
BMC Gastroenterol. 2021 Nov 23;21(1):438. doi: 10.1186/s12876-021-02030-x.
9
Patient Perspectives on Improving Patient-Provider Relationships and Provider Communication During Opioid Tapering.患者视角下的阿片类药物递减过程中改善医患关系和医患沟通。
J Gen Intern Med. 2022 May;37(7):1722-1728. doi: 10.1007/s11606-021-07210-9. Epub 2022 Jan 6.
10
A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.一项基于社区队列的慢性特发性便秘与便秘型肠易激综合征直接医疗服务提供者医疗成本的病例对照比较。
J Med Econ. 2017 Mar;20(3):273-279. doi: 10.1080/13696998.2016.1253584. Epub 2016 Nov 10.
本文引用的文献
1
Managing IBS-C: Focus on Symptom Control.管理便秘型肠易激综合征：关注症状控制。
Gastroenterol Hepatol (N Y). 2024 Apr;20(4):216-226.
2
Mechanism of Action Considerations in the Management of IBS-C.IBS-C管理中的作用机制考量
Gastroenterol Hepatol (N Y). 2023 Dec;19(12):749-756.
3
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.替那诺尔治疗便秘型肠易激综合征患者临床试验期间的腹部症状改善：一项事后分析
Am J Gastroenterol. 2024 May 1;119(5):937-945. doi: 10.14309/ajg.0000000000002685. Epub 2024 Jan 31.
4
Differential Diagnosis of Chronic Diarrhea: An Algorithm to Distinguish Irritable Bowel Syndrome With Diarrhea From Other Organic Gastrointestinal Diseases, With Special Focus on Exocrine Pancreatic Insufficiency.慢性腹泻的鉴别诊断：一种用于区分腹泻型肠易激综合征与其他器质性胃肠道疾病的算法，特别关注外分泌胰腺功能不全。
J Clin Gastroenterol. 2023 Aug 1;57(7):663-670. doi: 10.1097/MCG.0000000000001855.
5
Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.当前治疗慢性特发性便秘和伴有便秘的肠易激综合征的药物作用机制。
Am J Gastroenterol. 2022 Apr 1;117(4S):S6-S13. doi: 10.14309/ajg.0000000000001687.
6
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.肠道上皮屏障的炎症与微生物群相关调节
Front Nutr. 2021 Sep 13;8:718356. doi: 10.3389/fnut.2021.718356. eCollection 2021.
7
Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders.功能性肠病患者便秘和腹泻症状的改善与腹痛的缓解相关。
Neurogastroenterol Motil. 2022 Apr;34(4):e14253. doi: 10.1111/nmo.14253. Epub 2021 Sep 14.
8
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.系统评价与网状Meta分析：已获许可药物治疗便秘型肠易激综合征腹胀的疗效
Aliment Pharmacol Ther. 2021 Jul;54(2):98-108. doi: 10.1111/apt.16437. Epub 2021 Jun 11.
9
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).Tenapanor 治疗便秘型肠易激综合征患者的疗效：一项 26 周、安慰剂对照的 3 期试验（T3MPO-2）。
Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056.
10
ACG Clinical Guideline: Management of Irritable Bowel Syndrome.ACG 临床指南：肠易激综合征的管理。
Am J Gastroenterol. 2021 Jan 1;116(1):17-44. doi: 10.14309/ajg.0000000000001036.
Zotero 插件